Surgepays Inc SURG.OQ SURG.O is expected to show a fall in quarterly revenue when it reports results on November 12 for the period ending September 30 2024
The Bartlett Tennessee-based company is expected to report a 74.7% decrease in revenue to $8.642 million from $34.16 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Surgepays Inc is for a loss of 27 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Surgepays Inc is 5.50, above its last closing price of $1.52.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.09 | -0.07 | -0.66 | Missed | -842.9 |
Jan. 1 2024 | 0.14 | 0.15 | 0.07 | Missed | -53.3 |
Dec. 31 2023 | 0.41 | 0.41 | 0.19 | Missed | -53.3 |
Sep. 30 2023 | 0.28 | 0.29 | 0.49 | Beat | 71.9 |
Jun. 30 2023 | 0.15 | 0.16 | 0.40 | Beat | 158.1 |
Mar. 31 2023 | -0.03 | -0.03 | 0.31 | Beat | 1,133.3 |
Dec. 31 2022 | -0.19 | -0.11 | 0.25 | Beat | 317.4 |
Jan. 1 0001 | 0.29 | 0.29 | -0.12 | Missed | -141.4 |
This summary was machine generated November 9 at 00:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。